Focus:
Deal News
-
17 April 2019
Pulmatrix and Cipla collaborate to develop asthma drug
Pulmatrix and Cipla Technologies have signed a definitive agreement to jointly develop and commercialise Pulmazole to treat allergic bronchopulmonary aspergillosis (ABPA) in asthma patients.
-
17 April 2019
Gilead and insitro team up to develop treatment for NASH
Gilead Sciences has partnered with insitro, a data-driven drug discovery startup, to leverage an artificial intelligence based platform for the discovery and development of new drugs to treat nonalcoholic steatohepatitis.
-
16 April 2019
Catalent to buy gene therapy manufacturer Paragon for $1.2bn
Catalent, a provider of biologic drug development and manufacturing services, has signed a definitive agreement to acquire gene therapy manufacturing company Paragon Bioservices for $1.2bn.
-
16 April 2019
Enesi Pharma partners with US BARDA on new flu vaccines
UK-based Enesi Pharma has partnered with the US Biomedical Advanced Research and Development Authority to create new vaccines for protection from influenza.
-
16 April 2019
DNAnexus, Sutter Health and UPMC launch multiple sclerosis study
DNAnexus and Sutter Health have partnered with the University of Pittsburgh Medical Center to launch a clinico-genomic study aimed at improving personalised therapy for multiple sclerosis patients.
-
15 April 2019
Bristol-Myers $74bn Celgene takeover gets shareholders approvals
Bristol-Myers Squibb has secured shareholders’ approval for its $74bn acquisition of biotechnology company Celgene. More than 75% of the shareholders voted in favour of the merger agreement.
-
12 April 2019
AskBio secures $235m investment to accelerate growth
Gene therapy company Asklepios BioPharmaceutical has received an investment of $225m from TPG Capital and Vida Ventures to accelerate its long-term growth.
-
12 April 2019
Sandoz to commercialise Shionogi’s Rizmoic in European markets
Novartis unit Sandoz has entered an agreement to commercialise Japanese pharmaceutical company Shionogi’s drug Rizmoic (naldemedine) in the UK, Germany and the Netherlands.
-
11 April 2019
Pfizer to use Concerto HealthAI technology for cancer treatments
Pfizer has partnered with patient-centred research firm Concerto HealthAI to fast-track actionable patient insights for investigational and commercialised cancer therapies.
-
10 April 2019
Regeneron and Alnylam partner on eye and CNS disease therapies
Regeneron Pharmaceuticals has formed an alliance with Alnylam Pharmaceuticals for the discovery, development and commercialisation of new RNA interference therapies.
Go Top
